Pfizer announced that the FDA has approved the use of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single dose in adults ≥50 years of age for active immunization in the prevention of pneumonia and invasive disease. This approval was based on safety and immunogenicity studies involving approximately 6,000 adults ≥50 years. In these trials, vaccination with Prevnar 13 was shown to induce a functional antibody response to the 13 serotypes contained in the vaccine, including individuals previously vaccinated with the conventional pneumococcal polysaccharide vaccine (PPSV) and those naive to pneumococcal vaccines.
Prevnar 13 is already indicated for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine in children 6 weeks to 5 years of age.
For more information, call (800) 505-4426 or visit www.prevnar13.com.